Morgan Stanley Avalo Therapeutics, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$3.0 - $10.45 $104,595 - $364,339	-34,865 Reduced 46.29%	40,450 $20,000
Q2 2022 Aug 15, 2022	SELL	$3.0 - $10.45 $104,595 - $364,339	-34,865 Reduced 46.29%	40,450 $20,000
Q1 2022 Oct 27, 2022	BUY	$7.57 - $21.72 $263,928 - $757,267	34,865 Added 86.19%	75,315 $54,000
Q1 2022 May 13, 2022	SELL	$7.57 - $21.72 $599,104 - $1.72 Million	-79,142 Reduced 51.24%	75,315 $54,000
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $1.59 Million - $2.31 Million	80,632 Added 109.22%	154,457 $262,000
Q3 2021 Nov 15, 2021	BUY	$26.16 - $40.68 $1.93 Million - $3 Million	73,825 New	73,825 $160,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $91.1M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.